medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2010, Number 1

<< Back Next >>

Rev Esp Med Quir 2010; 15 (1)

Impact of prolonged treatment with valproate monotherapy in children with epilepsy on bone mineral density

Carrizosa MN, Solórzano GE, Vergara LA, Flores PAA, Martínez FM

Language: Spanish
References: 26
Page: 18-26
PDF size: 386.04 Kb.


ABSTRACT

Objective: To determine whether children with epilepsy treated with valproate monotherapy for more than six months have changes in bone mineral density.
Material and method: Comparative study, cross-matched for gender and age in 60 children, healthy children and for handling cases that received anti-epileptic valproate as the single for at least six months, the areas measured by the densitometer, were the lumbar region (L1 to L4) and hip.
Results: We found by descriptive statistics, which matched samples were appropriately according to measures of age, weight, height, physical activity and intake of calcium, the average duration of treatment was 3.4 years. By applying analytical statistics was determined that children taking valproate have six times more likely to have osteopenia on those not taken and that this is more important in those who require high doses and for more time.
Conclusion: Children who take valproate as monotherapy for more than six months have six times more risk of osteopenia compared with those not taking the drug.


REFERENCES

  1. Arzimanoglou A. Aicardi´s Epilepsy in Children. 3rd ed. USA: Ed. Lippincot Williams & Wilkins, 2004;pp:1-6.

  2. Rubio D. Actualidades en Epilepsia. Programa prioritario de epilepsia. México 2006. www.epilepsiamexico.gob.mx.

  3. López-Hernández E, Bravo J, Solís H. Epilepsia y antiepilépticos de primera y segunda generación, aspectos básicos útiles en la práctica. Laboratorio de Neurofisiología. Departamento de Anatomía. Facultad de Medicina, UNAM, 1991:1-8.

  4. Johannessen CU. Mechanisms of action of valproate: a commentator. Neurochem Int 2000;37:103-110.

  5. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90:21-34.

  6. Perucca E. An introduction to antiepileptic drugs. Epilep 2005;46(4):S31-37.

  7. Cummings S, Bates D, Black D. Clinical use of bone densitometry. JAMA 2002;288(15):1889-1897.

  8. Shaw N. Management of osteoporosis in children. Europ J Endocrin 2008(159):S33-39.

  9. Cons M. Densitometría ósea. En: Reza A, Mendoza V, editores. Enfermedades del metabolismo óseo y mineral. 1ª ed. México: Prado, 2006;pp:117-170.

  10. Horlick M, Wang J. Prediction models for evaluation of totalbody bone mass with dual-energy X-ray absorptiometry among children and adolescents. Pediatr 2004;114:e337-e345.

  11. Molgaard C, Thomsen B. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9-15.

  12. Kalkwarf H, Zemel B, Gilsanz V, et. Al. Pediatric bone mineral reference values. J Clinic Endocrinol Metab 2007;92(6):2087-2099.

  13. Samaniego E, Raj D, Sheth R. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol 2007;14:196-200.

  14. Andress DL, Ozuna J, Trischwell A. Antiepileptic drug induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786.

  15. Sheth R, Wesolowski C. Effect of carbamazepine and valproic acid on bone mineral density. J Pediatr 1995;127(2):256-262.

  16. Gülden K, Taner E. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clinic Pediatr 1999;38(2):93-98.

  17. Guo C, Ronen G, Atkinson S. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42(9):1141-1147.

  18. Farhat G, Yamout B. Effect of antiepileptic drugs one bone density in ambulatory patients. Neurol 2002;58(9):1348-1353.

  19. Ecevit C, Aydogan A. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004;31(4):279-282.

  20. Babayigit A, Dirik E, Bober E. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006;35(3):177-181.

  21. Souverein P, Webb D, Weil J, et al. Use of antiepileptic drugs and risk of fractures. Neurol 2006;66:1318-1324.

  22. Sheth D, Binkley N, Bruce P, Hermann A. Progressive bone deficit in epilepsy. Neurol 2008;70:170-176.

  23. The National Institute of Health [NIH Consensus Conference] Optimal Calcium Intake. JAMA 1994;272(24):1942-1948.

  24. Tablas de valor nutritivo de los alimentos de mayor consumo en Latinoamérica. En Sistema mexicano de alimentos equivalentes. Sistema de alimentos equivalentes. INNSZ e Instituto Nacional de Cardiología. México, 1996.

  25. Instructivo Beckman Coulter CX-4CE/CX-DELTA. Beckman Instruments Inc. Agentes diagnósticos para uso in vitro: ALP, PO4 y Ca. Alemania, 1995.

  26. Siberry G, Iannone R. Blood chemistries and body fluids. En: Siberry G, editor. The Harriet Lane Handbook. 15th ed. Madrid: Mosby, 2003; pp:119-126.




2020     |     www.medigraphic.com